Algo version: 0.98b
StageZero Life Sciences is listed at the TSX Exchange
StageZero Life Sciences [SZLS.TO]
TSX Sector: Healthcare Industry:Medical - Diagnostics & Research

Is StageZero Life Sciences stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

We cannot find any recorded dividends paid in our systems.

Sorry, we do not have any analyst data for this ticker

We cannot find data for StageZero Life Sciences 10 years ago, but if you had invested on Monday 9th of September 2019 when the price was $0.880, you would have made a loss of $-0.840 per share or -95.45%

We do not have enough data to give you this answer.

StageZero Life Sciences has much of the business financed by loans. This puts the company at high risk in periods of high inflation where borrowing costs usually go up. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.

We have calculated the inflation risk for StageZero Life Sciences to be high [1 of 1]

US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.